Clinical practice guidelines for diagnostic and treatment of the chronic heart failure

Abel A Pavía-López1, José A Magaña-Serrano2,3, José A Cigarroa-López4

  • 1Coordinador de las Guías Mexicanas de Práctica Clínica de la Sociedad Mexicana de Cardiología, Centro Médico ABC, Ciudad de México, México.

PubMed

Insights

This clinical practice guide provides evidence-based recommendations for diagnosing and treating chronic heart failure in Mexico. It aims to improve clinical decision-making and patient outcomes for heart failure management.

Area of Science:

  • Cardiology
  • Public Health

Background:

  • Chronic heart failure (CHF) is a leading cause of mortality and reduced quality of life globally.
  • Mexico faces a high prevalence of CHF risk factors, including hypertension, diabetes, and obesity.
  • There is a critical need for evidence-based guidelines for healthcare professionals managing CHF patients in Mexico.

Purpose of the Study:

  • To establish a clinical practice guide (CPG) for the diagnosis and treatment of chronic heart failure.
  • To provide evidence-based recommendations for healthcare professionals involved in CHF patient care.
  • To improve clinical decision-making and enhance the quality of care for CHF patients.

Main Methods:

  • Developed by the Mexican Society of Cardiology (SMC) in collaboration with the Iberic American Agency for the Development and Evaluation of Health Technologies.
  • Adhered to international quality standards (IOM, NICE, SIGN, G-I-N).
  • Utilized a modified Delphi panel methodology with an interdisciplinary expert group and methodologists experienced in systematic reviews.

Main Results:

  • A comprehensive CPG with consensus-based recommendations for CHF management was developed.
  • The guide integrates the best available evidence for clinical decision support.
  • Recommendations cover all clinical stages of chronic heart failure.

Conclusions:

  • This CPG serves as a crucial reference for clinicians managing chronic heart failure patients.
  • Implementation is expected to improve the quality of clinical care and patient quality of life.
  • The guide aims to reduce complications associated with chronic heart failure.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370